Stereoselective pharmacokinetics of ketamine and norketamine after constant rate infusion of a subanesthetic dose of racemic ketamine or S-ketamine in Shetland ponies

American Journal of Veterinary Research

Volumn 70, Issue 7, 2009, Pages 831-839

  Larenza, M Paula ^a,c   Peterbauer, Christoph ^a,d   Landoni, M Fabiana ^b   Levionnois, Olivier L ^a   Schatzmann, Urs ^a   Spadavecchia, Claudia ^a   Thormann, Wolfgang ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIODEGRADATION; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DRUG DISPOSITION; DRUG ELIMINATION; ENANTIOMER; HORSE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; STEREOCHEMISTRY;

ANIMALS; AREA UNDER CURVE; HALF-LIFE; HORSES; KETAMINE; MALE;

ANIMALIA; EQUIDAE;

EID: 67649528728     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.7.831     Document Type: Article

References (35)

1. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998;87:1186-1193. (Pubitemid 28501183)
2. Doenicke A, Kugler J, Mayer M, et al. Ketamine racemate or S-(+)-ketamine and midazolam. The effect on vigilance, efficacy and subjective findings[in German]. Anaesthesist 1992;41:610-618.
3. Larenza MP, Knobloch M, Landoni MF et al. Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration in Shetland ponies sedated with xylazine. Vet J 2008;177:432-435. (Pubitemid 351891503)
4. Kharasch ED, Labroo R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 1992;77:1201-1207. (Pubitemid 23001132)
5. Knobloch M, Portier CJ, Levionnois OL, et al. Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicol Appl Pharmacol 2006;216:373-386. (Pubitemid 44596230)
6. Schmitz A, Portier C, Thormann W, et al. Stereoselective biotransformation of ketamine in equine liver and lung microsomes. J Vet Pharmacol Ther 2008;31:446-455.
7. Fielding CL, Brumbaugh GW, Matthews NS, et al. Pharmacokinetics and clinical effects of a subanesthetic continuous rate infusion of ketamine in awake horses. Am J Vet Res 2006;67:1484-1490. (Pubitemid 44400163)
8. Lankveld DP, Driessen B, Soma LR, et al. Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. J Vet Pharmacol Ther 2006;29:477-488. (Pubitemid 44684090)
9. Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (part I). Clin Pharmacokinet 1989;17:175-199.
10. Peterbauer C, Larenza PM, Knobloch M, et al. Effects of a low dose infusion of racemic and S-ketamine on the nociceptive withdrawal reflex in standing ponies. Vet Anaesth Analg 2008;35:414-423.
11. Gasthuys F, De Moor A, Parmentier D. Haemodynamic changes during sedation in ponies. Vet Res Commun 1990;14:309-327.
12. Theurillat R, Knobloch M, Schmitz A, et al. Enantioselective analysis of ketamine and its metabolites in equine plasma and urine by CE with multiple isomer sulfated beta-CD. Electrophoresis 2007;28:2748-2757. (Pubitemid 47250280)
13. Schwartz G. Estimating the dimension of a model. Ann Stat 1978;6:461-464.
14. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175. (Pubitemid 8384279)
15. Rowland M, Tozer T. Concepts and applications. In: Febiger L, ed. Clinical pharmacokinetics. 3rd ed. London: Wolters Kluwer Health, 1995;75.
16. Ihmsen H, Geisslinger G, Schuttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001;70:431-438. (Pubitemid 33135322)
17. Larenza MP, Landoni MF, Levionnois OL, et al. Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration during isoflurane anaesthesia in Shetland ponies. Br J Anaesth 2007;98:204-212.
18. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-125. (Pubitemid 29317524)
19. Lam G, Chiou WL. Determination of the steady-state volume of distribution using arterial and venous plasma data from constant infusion studies with procainamide. J Pharm Pharmacol 1982;34:132-134.
20. Larenza MP, Ringer SK, Kutter APN, et al. Evaluation of anesthesia recovery quality after low-dose racemic or S-ketamine infusions during anesthesia with isoflurane in horses. Am J Vet Res 2009;70:710-718.
21. White PF, Marietta MP, Pudwill CR, et al. Effects of halothane anesthesia on the biodisposition of ketamine in rats. J Pharmacol Exp Ther 1976;196:545-555.
22. Nolan A, Reid J, Welsh E, et al. Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. Res Vet Sci 1996;60:262-266. (Pubitemid 26151132)
23. Henthorn TK, Krejcie TC, Niemann CU, et al. Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. Anesthesiology 1999;91:1733-1743.
24. Geisslinger G, Hering W, Thomann P, et al. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993;70:666-671. (Pubitemid 23169062)
25. White M, de Graaff P, Renshof B, et al. Pharmacokinetics of S(+) ketamine derived from target controlled infusion. Br J Anaesth 2006;96:330-334. (Pubitemid 43280624)
26. Upton RN, Ludbrook GL, Grant C, et al. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. Anesth Analg 1999;89:545-552. (Pubitemid 29409795)
27. Eilers H, Niemann C. Clinically important drug interactions with intravenous anaesthetics in older patients. Drugs Aging 2003;20:969-980. (Pubitemid 37363659)
28. Gepts E, Shafer SL, Camu F, et al. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 1995;83:1194-1204.
29. Schumacher GE. Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharm 1985;4:84-92.
30. White PF, Pudwill CR, Johnston RR, et al. Effects of halothane anesthesia on ketamine biotransformation. Proc West Pharmacol Soc 1976;19:227-231.
31. Woestenborghs RJ, Timmerman PM, Cornelissen ML, et al. Assay methods for sufentanil in plasma. Radioimmunoassay versus gas chromatography-mass spectrometry. Anesthesiology 1994;80:666-670.
32. Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991;21:285-307.
33. Kaka JS, Klavano PA, Hayton WL. Pharmacokinetics of ketamine in the horse. Am J Vet Res 1979;40:978-981.
34. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;30:853-858.
35. Marietta MP, Way WL, Castagnoli N Jr, et al. On the pharmacology of the ketamine enantiomorphs in the rat. J Pharmacol Exp Ther 1977;202:157-165.